Summary — H 136 (Session Law Chapter 246)
Topic: 340B Drug Pricing Program reporting (Idaho)
Status and key dates
- Enacted and signed by the Governor: April 1, 2025.
- Session Law Chapter: 246.
- Effective (emergency): July 1, 2025.
- Introduced: February 4, 2025.
Purpose
- Require annual state reporting from entities participating in the federal 340B drug pricing program to increase transparency about program participation and financial flows in Idaho.
Who is affected
- “340B covered entities” — defined as entities authorized under federal law to participate in 340B and expressly includes pharmacies under contract to dispense 340B drugs.
- State agencies: Idaho Department of Health & Welfare (IDHW), State Controller’s Office, and the Attorney General’s Office.
- Indirectly affects payers (commercial insurers, Medicaid, Medicare), contract pharmacies, and the entities’ patients.
Key provisions
1. Annual reporting requirement (due April 1 each year, covering the previous calendar year): covered entities must submit to IDHW, the State Controller, and the Attorney General:
- Entity name;
- Aggregate acquisition cost for prescription drugs obtained under 340B;
- Aggregate payment amount received for those drugs dispensed to patients;
- Aggregate payments made to contract pharmacies to dispense 340B drugs;
- Number of claims for those prescription drugs; and
- How savings from 340B participation were used, including amounts applied to charity care, community benefits, or similar uncompensated care programs.
2. Reports must break out the information by payer type: Commercial, Medicaid, and Medicare.
3. Confidentiality: Individual data submitted under these requirements is confidential and not available for public inspection.
4. State Controller’s aggregation/reporting (due annually before November 15): the Controller will aggregate submitted data, submit an electronic report to the Legislative Council, and publish the aggregated report on the Transparent Idaho website.
5. Attorney General authority: may use reported information to investigate Medicaid fraud and to ensure compliance with Health Resources & Services Administration (HRSA) requirements related to the 340B program.
Fiscal impact
- Fiscal note attached to the bill claims no net fiscal impact to state or local government (no revenue or expenditure change).
Practical impact and considerations
- Imposes an annual data collection and reporting obligation on 340B entities (including contract pharmacies).
- Balances data confidentiality for submitted records with public availability of aggregated state-level reporting.
- Provides state authorities tools to monitor Medicaid-related issues and federal compliance, while aiming to give legislators and the public aggregated transparency into 340B financial flows and use of savings.
